Articles Delivering pharma innovation: Takeda and Novo Nordisk on the... Andrew McConaghie reviews the findings of the latest pharma ranking index, which assesses on the premise: if you gave the same molecule to two different companies in early phase, which would ma
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.